Hims & Hers Health (NYSE:HIMS) Stock Price Down 3.8% – Time to Sell?

Hims & Hers Health, Inc. (NYSE:HIMS) shares dropped 3.8% during mid-day trading on Monday . The stock traded as low as $43.81 and last traded at $47.40. Approximately 17,903,515 shares changed hands during mid-day trading, an increase of 0% from the average daily volume of 17,886,535 shares. The stock had previously closed at $49.28.

Analyst Ratings Changes

HIMS has been the topic of several analyst reports. Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Deutsche Bank Aktiengesellschaft raised their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. TD Cowen restated a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Morgan Stanley downgraded Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Finally, Citigroup cut Hims & Hers Health from a “neutral” rating to a “sell” rating and boosted their price objective for the company from $24.00 to $25.00 in a research report on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $28.53.

Hims & Hers Health Price Performance

The stock’s fifty day moving average price is $35.05 and its 200-day moving average price is $25.83. The firm has a market cap of $11.03 billion, a PE ratio of 114.94 and a beta of 1.35.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $33.56, for a total transaction of $68,932.24. Following the transaction, the insider now owns 184,947 shares of the company’s stock, valued at approximately $6,206,821.32. The trade was a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Soleil Boughton sold 2,343 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $29.90, for a total value of $70,055.70. Following the completion of the sale, the insider now directly owns 165,254 shares of the company’s stock, valued at $4,941,094.60. This trade represents a 1.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,082,618 shares of company stock valued at $37,317,410. Corporate insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors have recently bought and sold shares of HIMS. Mackenzie Financial Corp grew its stake in shares of Hims & Hers Health by 44.6% in the 4th quarter. Mackenzie Financial Corp now owns 29,096 shares of the company’s stock valued at $704,000 after buying an additional 8,977 shares during the period. Public Employees Retirement System of Ohio acquired a new position in Hims & Hers Health in the fourth quarter valued at approximately $99,000. Neo Ivy Capital Management grew its position in Hims & Hers Health by 145.4% in the fourth quarter. Neo Ivy Capital Management now owns 166,734 shares of the company’s stock worth $4,031,000 after acquiring an additional 98,798 shares during the period. PharVision Advisers LLC acquired a new stake in Hims & Hers Health during the fourth quarter worth $234,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Hims & Hers Health by 31.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,156 shares of the company’s stock valued at $8,225,000 after purchasing an additional 81,495 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.